GalNAc exploits millions of rapidly recycling receptors on hepatocytes to deliver siRNA with remarkable efficiency, enabling durable gene silencing after subcutaneous dosing while highlighting the unresolved challenge of extrahepatic RNA delivery.
LSI Medience has validated Pillar’s oncoReveal Essential+ for cfDNA and cfRNA screening, with approximately 2,000 lung cancer patients expected to enter testing over two years.
Nipro’s newly FDA-cleared ELISIO-HX is designed to remove larger uremic middle molecules while retaining essential proteins and working with existing hemodialysis infrastructure.
Japan approves IMCIVREE for acquired hypothalamic obesity, expanding Rhythm Pharmaceuticals’ global franchise. See what the approval means for growth.
ERAS-0015 wins FDA Fast Track status after a 57% early response signal in KRAS pancreatic cancer as Erasca prepares three registration-focused trials.
FDA extends deramiocel review to November 22 as Capricor submits new HOPE-3 data supporting an upper limb function indication in Duchenne.
STAIR-HIV will randomize 30 virally suppressed adults to weekly alendronate or placebo, testing whether a familiar osteoporosis medicine can perturb persistent HIV reservoirs despite continued ART.
Ipsen has completed its Kartos Therapeutics acquisition, paying $450 million upfront with up to $1.3 billion in milestones while the 600-patient POIESIS trial tests navtemadlin plus ruxolitinib.
FDA is actively encouraging organoids, organs-on-chips and computational models as alternatives to some animal studies, but reproducibility, validation and whole-body biology still prevent a simple one-for-one replacement.
Wellspect has launched a suction-based urine collection system for home use in the United States, completing a Surity portfolio built around female and male external catheters rather than indwelling drainage.